ABSTRACT - 599669 The disclosure relates to a therapeutically effective aqueous ophthalmic composition comprising a solubility enhancing component (SEC) selected from the group consisting of povidone, polyvinyl alcohol and sodium carboxymethyl cellulose, a preservative selected from the group consisting of a quaternary ammonium preservative, an oxidative preservative, and a biguanide preservative, and 0.1% (w/v) of 5-bromo-6-(2-imidozolin-2-ylamino) quinoxaline tartrate (brimonidine tartrate), wherein the composition has a pH of 7-9.
